3164 Federal Register / Vol. 86, No. 9 / Thursday, January 14, 2021 / Notices 

immunotherapy using autologous 

human T cells transduced with 

lentiviral vectors, wherein the viral 

transduction leads to the expression of 

a CAR that targets CD33 (comprised of 

the CD33-binding domain referenced as 

Hu195 or hP67.6 in the invention as 

well as an intracellular signaling 

domain), for the prophylaxis or 

treatment of CD33-expressing cancers. 

For clarity, ‘‘CD33-specific logic-gated 

CAR-based immunotherapy’’ means 

therapies where the CAR-expressing T 

cells recognize CD33 and are engineered 

to respond to one or more additional 

antigens (but not necessarily all of the 

antigens). 

2. The development of a CD33- 

specific logic-gated CAR-based 

immunotherapy using allogeneic human 

NK cells transduced with retroviral 

vectors, including but not limited to 

lentiviral vectors, wherein the viral 

transduction leads to the expression of 

a CAR that targets CD33 (comprised of 

the CD33-binding domain referenced as 

Hu195 or hP67.6 in the invention as 

well as an intracellular signaling 

domain), for the prophylaxis or 

treatment of CD33-expressing cancers. 

For clarity, ‘‘CD33-specific logic-gated 

CAR-based immunotherapy’’ means 

therapies where the CAR-expressing NK 

cells recognize CD33 and are engineered 

to respond to one or more additional 

antigens (but not necessarily all of the 

antigens). 

These technologies disclose therapies 

to treat AML by utilizing CARs that 

recognize AML cells through a binder 

for CD33. The CD33 binders are known 

as Hu195 or hP67.6. CD33 is a well 

validated immunotherapeutic target that 

is expressed on the surface of malignant 

cells, most notably on the surface of 

acute myelogenous leukemia (AML) 

blasts. 

This Notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published Notice, the National 

Cancer Institute receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information from these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: January 7, 2021. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2021–00637 Filed 1–13–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; HHS–NIH–CDC–SBIR PHS 

2021–1 Phase I: Production of Adjuvants 

Mimics (Topic 093) (For SBIRs Phase I) 

Date: February 1, 2021. 

Time: 11:00 a.m. to 1:30 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F52, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Maggie A. Morris Fears, 

Ph.D., Scientific Review Officer, Scientific 

Review Program, Division of Extramural 

Activities, National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F52, 

Rockville, MD 20852, 301–761–5444, 

maggie.morrisfears@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; HHS–NIH–CDC–SBIR PHS 

2021–1 Phase I: Adjuvant Discovery for 

Vaccines and for Autoimmune and Allergic 

Disease (Topic 092) (For SBIRs Phase I). 

Date: February 1, 2021. 

Time: 1:30 p.m. to 2:30 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F52, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Maggie A. Morris Fears, 

Ph.D., Scientific Review Officer, Scientific 

Review Program, Division of Extramural 

Activities, National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F52, 

Rockville, MD 20852, 301–761–5444, 

maggie.morrisfears@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; HHS–NIH–CDC–SBIR PHS 

2021–1 Phase II: Adjuvant Discovery for 

Vaccines and for Autoimmune and Allergic 

Disease (Topic 092) (For SBIRs Phase II). 

Date: February 1, 2021. 

Time: 2:30 p.m. to 4:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F52, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Maggie A. Morris Fears, 

Ph.D., Scientific Review Officer, Scientific 

Review Program, Division of Extramural 

Activities, National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F52, 

Rockville, MD 20852, 301–761–5444, 

maggie.morrisfears@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: January 8, 2021. 

Tyeshia M. Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–00573 Filed 1–13–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 


khammond on DSKJM1Z7X2PROD with NOTICES